Zykadia 150 mg (Ceritinib 150 mg per capsule/tablet) by Novartis.
Indications: ALK-positive advanced non-small cell lung cancer.
Administration: Oral: 450 mg once daily with food.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Novartis |
| Active ingredient | Ceritinib 150 mg per capsule/tablet — ALK inhibitor. |
| Strength & pack | 150 hard capsules or 84 film-coated tablets, depending on market. |
| Form | Capsules / film-coated tablets |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |